Navigation Links
Pfizer Declares A 20-Cent First-Quarter 2011 Dividend
Date:12/13/2010

NEW YORK, Dec. 13, 2010 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent first-quarter 2011 dividend on the company's common stock, payable March 1, 2011, to shareholders of record at the close of business on February 4, 2011.  Pfizer increased the dividend by approximately 11 percent, to 20 cents from 18 cents per share.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

"This dividend increase is a testament to our commitment to enhance shareholder value and reflects continued confidence in our business," said Ian Read, Pfizer President and Chief Executive Officer. "While the dividend level remains a decision of the board and will continue to be evaluated in the context of future business performance, barring significant unforeseen events, we continue to target a dividend payout ratio comparable to the current industry average of approximately 40 percent in about three years."  

The first-quarter 2011 cash dividend will be the 289th consecutive quarterly dividend paid by Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of December 13, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company's future financial performance as well as general economic, political, business, industry, regulatory and market conditions. A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Young Children In Developing World Receive Accelerated Access to Pfizers Prevenar 13 Vaccine
2. Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer
3. Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
6. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
7. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
8. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
9. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
10. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
11. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology:
(Date:2/27/2017)... Sedona, Arizona (PRWEB) , ... February 27, 2017 ... ... Premier Center for Shamanic Healing and Spiritual Awakening, is happy to announce ... reboot for mind and body, these individual customized retreats offer the winter-weary soul ...
(Date:2/27/2017)... ... 27, 2017 , ... This webinar , sponsored by ... tool to characterize particle size distributions in the field of geoscience and soil ... scientific findings. It describes methods of optimized and standardized sample collection, preparation and ...
(Date:2/27/2017)... ... 27, 2017 , ... Silicon Valley Hair Institute, a professional ... informational post on robotic hair transplantation. San Francisco residents may be confused over ... Unit Transplantation (FUT) can sound similar. Either treatment can be used to provide ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will ... the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace ... analytics to improve Medicaid population health management. , ODH will also have an exhibit ...
Breaking Medicine News(10 mins):